Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

112,811 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.
Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D. Smolen JS, et al. Among authors: li z. Ann Rheum Dis. 2017 Jun;76(6):960-977. doi: 10.1136/annrheumdis-2016-210715. Epub 2017 Mar 6. Ann Rheum Dis. 2017. PMID: 28264816 Free article. Review.
APLAR rheumatoid arthritis treatment recommendations.
Lau CS, Chia F, Harrison A, Hsieh TY, Jain R, Jung SM, Kishimoto M, Kumar A, Leong KP, Li Z, Lichauco JJ, Louthrenoo W, Luo SF, Nash P, Ng CT, Park SH, Suryana BP, Suwannalai P, Wijaya LK, Yamamoto K, Yang Y, Yeap SS; Asia Pacific League of Associations for Rheumatology. Lau CS, et al. Among authors: li z. Int J Rheum Dis. 2015 Sep;18(7):685-713. doi: 10.1111/1756-185X.12754. Int J Rheum Dis. 2015. PMID: 26334449 Review.
Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient-reported outcomes from a Phase 3 randomized controlled trial.
Li Z, An Y, Su H, Li X, Xu J, Zheng Y, Li G, Kwok K, Wang L, Wu Q. Li Z, et al. Among authors: li g, li x. Int J Rheum Dis. 2018 Feb;21(2):402-414. doi: 10.1111/1756-185X.13244. Epub 2018 Jan 4. Int J Rheum Dis. 2018. PMID: 29314645 Free PMC article. Clinical Trial.
Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study.
Takeuchi T, Genovese MC, Haraoui B, Li Z, Xie L, Klar R, Pinto-Correia A, Otawa S, Lopez-Romero P, de la Torre I, Macias W, Rooney TP, Smolen JS. Takeuchi T, et al. Among authors: li z. Ann Rheum Dis. 2019 Feb;78(2):171-178. doi: 10.1136/annrheumdis-2018-213271. Epub 2018 Sep 7. Ann Rheum Dis. 2019. PMID: 30194275 Free PMC article. Clinical Trial.
112,811 results
You have reached the last available page of results. Please see the User Guide for more information.